An update on calcium metabolism alterations and cardiovascular risk in patients with chronic kidney disease: Questions, myths and factss

Journal of Nephrology

Volumn 26, Issue 3, 2013, Pages 456-464

  Savica, Vincenzo ^a,b   Bellinghieri, Guido ^a   Monardo, Paolo ^b   Muraca, Ugo ^a   Santoro, Domenico ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Papardo Hospital   (Italy)

Author keywords

Calcium metabolism; Calcium binding agents; Salivary phosphorus; Vascular calcification

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CALCIUM CARBONATE; CINACALCET; CITRATE CALCIUM; LANTHANUM CARBONATE; MAGNESIUM; NICOTINIC ACID; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; SEVELAMER CARBONATE; VITAMIN D;

ABDOMINAL RADIOGRAPHY; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE DISEASE; CALCIUM INTAKE; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; COMPUTER ASSISTED TOMOGRAPHY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; ECHOGRAPHY; FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; MINERAL METABOLISM; MORTALITY; NONHUMAN; OSTEOPENIA; PRACTICE GUIDELINE; PROGNOSIS; PROTEINURIA; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SOFT TISSUE CALCIFICATION; SPINE FRACTURE; SURVIVAL; UNSPECIFIED SIDE EFFECT; UREMIA; VITAMIN D DEFICIENCY;

ARRHYTHMIAS, CARDIAC; BONE DISEASES; CALCIUM; CARDIOVASCULAR DISEASES; CHELATING AGENTS; HUMANS; POLYAMINES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVAL RATE; VASCULAR CALCIFICATION;

EID: 84877967391     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000189     Document Type: Article

References (57)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5)(Suppl 3):S112-S119.
2. Moe S, Drüeke T, Cunningham J, et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-S130.
4. Nordin BE. The effect of calcium supplementation on bone loss in 32 controlled trials in postmenopausal women. Osteoporos Int. 2009;20(12):2135-2143.
5. Feskanich D, Willett WC, Colditz GA. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Am J Clin Nutr. 2003;77(2):504-511.
6. Jackson RD, LaCroix AZ, Gass M, et al. Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669-683.
7. Reid IR, Grey AB, Bolland BJ. Calcium supplementation for older men and women? Osteoporos Int. 2008;19:1119-1123.
8. Cheng J, Zhang W, Zhang X, Li X, Chen J. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7(3):391-400.
9. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-38.
10. Block GA, Zeig S, Sugihara J, et al; TARGET Investigators. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant. 2008;23(7): 2311-2318.
11. Breitwieser GE, Miedlich SU, Zhang M. Calcium sensing receptors as integrators of multiple metabolic signals. Cell Calcium. 2004;35(3):209-216.
12. Schaub MC, Hefti MA, Zaugg M, Zaugg M. Integration of calcium with the signaling network in cardiac myocytes. J Mol Cell Cardiol. 2006;41(2):183-214.
13. Bailey JL, Zheng B, Hu Z, Price SR, Mitch WE. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol. 2006;17(5):1388-1394.
14. Chen X, Zhang X, Kubo H, et al. Ca2+ influx-induced sarcoplasmic reticulum Ca2+ overload causes mitochondrialdependent apoptosis in ventricular myocytes. Circ Res. 2005;97(10):1009-1017.
15. Harding SE, MacLeod KT, Jones SM, Vescovo G, Poole-Wilson PA. Contractile responses of myocytes isolated from patients with cardiomyopathy. Eur Heart J. 1991;12(Suppl D): 44-48.
16. Abriel HSJ, Schläpfer J, Keller DI, et al. Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy. Swiss Med Wkly. 2004;134 (47-48):685-694.
17. Choi BR, Burton F, Salama G. Cytosolic Ca2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome. J Physiol. 2002;543(Pt 2): 615-631.
18. Kögler H, Schott P, Toischer K, et al. Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+ ATPase expression. Circulation. 2006;113(23):2724-2732.
19. Wollert KC, Yurukova S, Kilic A, et al. Increased effects of C-type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP-dependent protein kinase I. Br J Pharmacol. 2003;140(7):1227-1236.
20. Kögler H, Schott P, Toischer K, et al. Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+ ATPase expression. Circulation. 2006;113(23):2724-2732.
21. Cannata-Andía JB, Rodríguez-García M, Carrillo-López N, Naves-Díaz M, Díaz-López B. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol. 2006;17(12)(Suppl 3):S267-S273.
22. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ. 2008;336(7638):262-266.
23. Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res. 2005;20(5):764-772.
24. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997;132(2):245-250.
25. Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant. 2004;19(6):1480-1488.
26. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731-1740.
27. Okuno S, Ishimura E, Kitatani K, et al. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2007;49(3):417-425.
28. Ogawa T, Ishida H, Akamatsu M, et al. Progression of aortic arch calcification and all-cause and cardiovascular mortality in chronic hemodialysis patients. Int Urol Nephrol. 2010;42(1):187-194.
29. Schlieper G, Krüger T, Djuric Z, et al. Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int. 2008;74(12):1582-1587.
30. Adragão T, Pires A, Birne R, et al. A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Nephrol Dial Transplant. 2009;24(3):997-1002.
31. Rodríguez-García M, Gómez-Alonso C, Naves-Díaz M, Diaz-Lopez JB, Diaz-Corte C, Cannata-Andía JB; Asturias Study Group. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant. 2009;24(1):239-246.
32. Adragao T, Branco P, Birne R, et al. Bone mineral density, vascular calcifications, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int. 2008;28(6):668-672.
33. Adragao T, Herberth J, Monier-Faugere MC, et al. Femoral bone mineral density reflects histologically determined cortical bone volume in hemodialysis patients. Osteoporos Int. 2010;21(4):619-625.
34. Combe C, Albert JM, Bragg-Gresham JL, et al. The burden of amputation among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2009;54(4):680-692.
35. Mazzaferro S, Pasquali M, Rotondi S, Tartaglione L. Does any therapy exist for vascular calcifications in uremia? J Nephrol. 2011;24(Suppl 18):S16-S24.
36. de Solis AJ, González-Pacheco FR, Deudero JJ, et al. Alkalinization potentiates vascular calcium deposition in an uremic milieu. J Nephrol. 2009;22(5):647-653.
37. Román-García P, Carrillo-López N, Fernández-Martín JL, Naves-Díaz M, Ruiz-Torres MP, Cannata-Andía JB. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone. 2010;46(1):121-128.
38. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68(4):1815-1824.
39. Borzecki AM, Lee A, Wang SW, Brenner L, Kazis LE. Survival in end stage renal disease: calcium carbonate vs. sevelamer. J Clin Pharm Ther. 2007;32(6):617-624.
40. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71 (5):438-441.
41. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130-1137.
42. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol. 2003;14(9)(Suppl 4):S305-S309.
43. London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19(9):1827-1835.
44. Bellinghieri G, Santoro D, Savica V. Emerging drugs for hyperphosphatemia. Expert Opin Emerg Drugs. 2007;12(3): 355-365.
45. Savica V, Calò LA, Monardo P, Santoro D, Bellinghieri G. Phosphate binders and management of hyperphosphataemia in end-stage renal disease. Nephrol Dial Transplant. 2006;21(8):2065-2068.
46. Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant. 2006;21(8):2217-2224.
47. Finn WF; SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006;65(3): 191-202.
48. Savica V, Calò LA, Caldarera R, et al. Phosphate salivary secretion in hemodialysis patients: implication fo the treatment of hyperphospatemia. Nephron Physiol. 2007;105(3): 52-55.
49. Savica V, Santoro D, Monardo P, Mallamace A, Bellinghieri G. Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis. Ther Clin Risk Manag. 2008;4(4):821-826.
50. Savica V, Calò LA, Granata A, et al. A new approach to the evaluation of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2007;68(4):216-221.
51. Savica V, Bellinghieri G, Santoro D. Phosphorus-related mechanisms of vascular calcification. Arch Intern Med. 2007; 167(21):2368.
52. Savica V, Calò LA, Santoro D, Monardo P, Granata A, Bellinghieri G. Salivary phosphate secretion in chronic kidney disease. J Ren Nutr. 2008;18(1):87-90.
53. Savica V, Calò LA, Monardo P, et al. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol. 2009;20(3):639-644.
54. Savica V, Bellinghieri G, Santoro D. Is it time to modify the target range for serum phosphorus levels in chronic kidney disease (CKD). J Ren Nutr. 2010;20(2):65.
55. Savica V, Calò LA, Santoro D, et al. Salivary glands: a new player in phosphorus metabolism. J Ren Nutr. 2011;21(1):39-42.
56. Elder GJ. Calcium supplementation: lessons from the general population for chronic kidney disease and back. Curr Opin Nephrol Hypertens. 2011;20(4):369-375.
57. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520-528.